Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1

Status

Recruiting 3Completed 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5CNS 1

Conditions

Breast Neoplasms 5Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Neoplasms by Site 1Neoplasms 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Advanced Breast Cancer 1Adenosarcoma of the uterus 1

Interventions

Fulvestrant 127Trastuzumab 117Paclitaxel 113Letrozole 109pembrolizumab 81palbociclib 76pertuzumab 75Capecitabine 74Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 65exemestane 63Tamoxifen 63ribociclib 61trastuzumab deruxtecan 57Specimen Handling 51Surveys and Questionnaires 50Radiotherapy 50Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 42olaparib 40Standard of Care 36Biopsy 33sacituzumab govitecan 32130-nm albumin-bound paclitaxel 32Exercise 30Doxorubicin 30eribulin 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Breast Neoplasms × RAD1901 × 1 year × Clear all
NCT05386108 2026-06-04

ELECTRA

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
73 enrolled
BreastCNS

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT07198724 2026-04-09

ERADICATE

Dana-Farber Cancer Institute

Phase 1/2 Recruiting
65 enrolled
Breast

Breast Neoplasms

NCT05963997 2026-03-23

SUMIT-ELA

Carrick Therapeutics Limited

Phase 1/2 Completed
49 enrolled
Breast

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

Dana-Farber Cancer Institute

Phase 2 Recruiting
297 enrolled
Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡